Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

PEN

Penumbra Inc

Dec 10 • 04:00PM ET

242.27

Dollar change +1.41
Percentage change 0.59	%

Healthcare • Medical Devices • USA • NYSE

Peers: BSX ISRG EW HOLX MDT JNJ ABT SYK ZBH TFX

| Held by: IJH VTI VB VXF VBK MDY IJK IHI IWP SPMD

Scroll to Statements

Index	-	P/E	281.35	EPS (ttm)	0.86	Insider Own	3.45%	Shs Outstand	38.36M	Perf Week	-1.21%
Market Cap	9.30B	Forward P/E	63.96	EPS next Y	3.79	Insider Trans	-6.85%	Shs Float	37.06M	Perf Month	2.46%
Income	34.55M	PEG	11.40	EPS next Q	0.89	Inst Own	92.61%	Short Float	4.99%	Perf Quarter	19.75%
Sales	1.16B	P/S	7.99	EPS this Y	33.54%	Inst Trans	-0.64%	Short Ratio	5.35	Perf Half Y	27.55%
Book/sh	28.78	P/B	8.42	EPS next Y	35.71%	ROA	2.34%	Short Interest	1.85M	Perf Year	8.14%
Cash/sh	7.58	P/C	31.95	EPS next 5Y	24.68%	ROE	3.13%	52W Range	148.00 - 277.34	Perf YTD	-3.69%
Dividend Est.	-	P/FCF	69.30	EPS past 5Y	66.20%	ROI	2.62%	52W High	-12.65%	Beta	0.52
Dividend TTM	-	Quick Ratio	3.25	Sales past 5Y	19.41%	Gross Margin	62.19%	52W Low	63.70%	ATR (14)	6.55
Dividend Ex-Date	-	Current Ratio	5.82	EPS Y/Y TTM	-15.07%	Oper. Margin	6.74%	RSI (14)	57.12	Volatility	2.64% 2.56%
Employees	4200	Debt/Eq	0.21	Sales Y/Y TTM	16.96%	Profit Margin	2.97%	Recom	1.89	Target Price	243.60
Option/Short	Yes / Yes	LT Debt/Eq	0.19	EPS Q/Q	220.86%	Payout	0.00%	Rel Volume	0.68	Prev Close	240.86
Sales Surprise	1.24%	EPS Surprise	23.73%	Sales Q/Q	11.11%	Earnings	Oct 30 AMC	Avg Volume	346.15K	Price	242.27
SMA20	0.32%	SMA50	8.70%	SMA200	17.55%	Trades		Volume	239,072	Change	0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-18-24	Initiated	Stifel	Buy	$238
Sep-03-24	Initiated	Leerink Partners	Outperform	$263
Jul-31-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$289 → $150
Jul-31-24	Downgrade	Citigroup	Buy → Neutral	$165 → $178
Feb-23-24	Downgrade	JP Morgan	Overweight → Neutral	$284 → $250
Sep-06-23	Initiated	Morgan Stanley	Equal-Weight	$265
Jul-19-23	Initiated	Robert W. Baird	Outperform	$375
Mar-29-23	Downgrade	Needham	Buy → Hold
Jan-30-23	Initiated	Piper Sandler	Overweight	$275
Nov-04-22	Upgrade	Citigroup	Neutral → Buy	$217 → $212
Oct-12-22	Initiated	Jefferies	Buy	$230
Oct-05-22	Downgrade	Citigroup	Buy → Neutral	$170 → $217
Sep-09-22	Upgrade	Needham	Hold → Buy
Jul-18-22	Initiated	RBC Capital Mkts	Outperform	$195
Apr-19-22	Initiated	Deutsche Bank	Buy	$250
Mar-08-22	Initiated	Needham	Hold
Sep-16-21	Initiated	Truist	Buy	$350
Jun-04-21	Upgrade	BTIG Research	Neutral → Buy	$291
Dec-16-20	Downgrade	BTIG Research	Buy → Neutral
Oct-07-20	Resumed	Canaccord Genuity	Buy	$253

Show Previous Ratings

Dec-09-24 12:45PM	Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Dec-06-24 09:45AM	Why Penumbra (PEN) is a Top Growth Stock for the Long-Term (Zacks)
Nov-29-24 11:31AM	Why Is Penumbra (PEN) Up 6.7% Since Last Earnings Report? (Zacks)
Nov-25-24 05:05PM	Penumbra, Inc. (PEN): Innovating in Thrombectomy and Embolization with New FDA-Approved Technologies (Insider Monkey)
Nov-21-24 12:45PM	3 Reasons Growth Investors Will Love Penumbra (PEN) (Zacks)
04:30PM	Loading…
Nov-20-24 04:30PM	Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
Nov-18-24 10:00AM	Inside a $400 billion bet on the brain-computer interface revolution (Yahoo Finance)
Nov-17-24 04:50PM	Penumbra, Inc. (PEN): A Bull Case Theory (Insider Monkey)
Nov-06-24 12:29PM	Penumbra reveals positive data for algorithm-assisted thrombectomy tech (Clinical Trials Arena)
Nov-05-24 12:45PM	Here is Why Growth Investors Should Buy Penumbra (PEN) Now (Zacks)
09:50AM	Here's Why Penumbra (PEN) is a Strong Momentum Stock (Zacks)
09:00AM	New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options (PR Newswire)
Nov-04-24 11:19AM	Implied Volatility Surging for Penumbra (PEN) Stock Options (Zacks)
Oct-31-24 03:15AM	Penumbra Inc (PEN) Q3 2024 Earnings Call Highlights: Strong U.S. ... (GuruFocus.com) +8.32%
Oct-30-24 06:30PM	Penumbra (PEN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:30PM	Loading…
05:30PM	Penumbra (PEN) Q3 Earnings and Revenues Top Estimates (Zacks)
04:24PM	Penumbra: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Penumbra, Inc. Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-23-24 10:02AM	Penumbra (PEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-15-24 10:31AM	Penumbra completes enrolment for THUNDER study to treat ischemic stroke (Medical Device Network)
Oct-14-24 06:20PM	Why Penumbra Stock Zoomed 4% Higher Today (Motley Fool)
09:00AM	Penumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke (PR Newswire)
Oct-10-24 09:00AM	Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism (PR Newswire)
Oct-09-24 07:50AM	Penumbra price target raised to $222 from $205 at RBC Capital (TipRanks)
Oct-02-24 04:30PM	Penumbra, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for October 30, 2024 (PR Newswire)
Sep-18-24 06:29PM	Why Penumbra Stock Zoomed Nearly 5% Higher Today (Motley Fool)
Sep-16-24 06:53AM	Penumbra secures CE mark for CAVT technologies in Europe (Medical Device Network)
03:00AM	Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies - Lightning Flash 2.0 and Lightning Bolt 7 - in Europe (PR Newswire)
Sep-06-24 01:49AM	Insider Sale: EVP, General Counsel & Secretary Johanna Roberts Sells Shares of Penumbra Inc ... (GuruFocus.com)
01:49AM	Insider Sale: Director Harpreet Grewal Sells Shares of Penumbra Inc (PEN) (GuruFocus.com)
11:31AM	Loading…
Aug-29-24 11:31AM	Why Is Penumbra (PEN) Up 20% Since Last Earnings Report? (Zacks)
06:55AM	Penumbra axes virtual reality division, will lay off 71 people (MedTech Dive)
Aug-27-24 04:30PM	Penumbra, Inc. to Present at the Baird Global Healthcare Conference (PR Newswire)
Aug-21-24 04:30PM	Penumbra, Inc. to Present at the Wells Fargo Healthcare Conference (PR Newswire)
08:03AM	Penumbra sees 85.5% limb salvage rate in thrombectomy device trial (Medical Device Network)
Aug-16-24 01:01AM	Insider Sale: EVP, General Counsel & Secretary Johanna Roberts Sells Shares of Penumbra Inc ... (GuruFocus.com)
Aug-13-24 07:00AM	Penumbra, Inc. Announces $200 Million Share Repurchase Authorization (PR Newswire) +10.75%
Aug-02-24 04:30PM	Penumbra, Inc. to Present at the Canaccord Genuity Growth Conference (PR Newswire)
Jul-31-24 01:50PM	Q2 2024 Penumbra Inc Earnings Call (Thomson Reuters StreetEvents)
10:03AM	Penumbra (PEN) Tops on Q2 Earnings, Lowers Sales View (Zacks)
Jul-30-24 08:56PM	PEN Stock Earnings: Penumbra Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
07:00PM	Penumbra (PEN) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:30PM	Penumbra (PEN) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:32PM	Penumbra: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Penumbra, Inc. Reports Second Quarter 2024 Financial Results (PR Newswire)
Jul-23-24 10:01AM	Penumbra (PEN) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-18-24 04:39AM	Penumbra (PEN) Soars 3.3%: Is Further Upside Left in the Stock? (Zacks) -6.11%
Jul-17-24 12:45PM	Looking for a Growth Stock? 3 Reasons Why Penumbra (PEN) is a Solid Choice (Zacks)
Jul-04-24 03:30AM	Insider Sale: EVP, General Counsel & Secretary Johanna Roberts Sells Shares of Penumbra Inc ... (GuruFocus.com)
Jul-02-24 04:05PM	Penumbra, Inc. Schedules Second Quarter 2024 Earnings Release and Conference Call for July 30, 2024 (PR Newswire)
Jun-13-24 09:45AM	Why Penumbra (PEN) is a Top Growth Stock for the Long-Term (Zacks)
Jun-06-24 11:31AM	Why Is Penumbra (PEN) Down 4.8% Since Last Earnings Report? (Zacks)
Jun-04-24 04:30PM	Penumbra, Inc. to Present at the Truist Securities MedTech Conference (PR Newswire)
May-23-24 04:30PM	Penumbra, Inc. to Present at the William Blair Growth Stock Conference (PR Newswire)
May-16-24 03:22AM	Insider Sale: EVP, General Counsel & Secretary Johanna Roberts Sells 600 Shares of Penumbra ... (GuruFocus.com)
May-15-24 07:41AM	Inari Medical (NARI) Fell on Investor Concerns (Insider Monkey)
May-13-24 12:08PM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 01:42PM	Penumbra, Inc. (NYSE:PEN) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:43AM	Penumbra (PEN) Q1 Earnings Lag Estimates, Margins Expand (Zacks)
May-07-24 05:35PM	Penumbra Inc (PEN) Surpasses Analyst Revenue Forecasts in Q1 2024 (GuruFocus.com)
04:42PM	Penumbra: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Penumbra, Inc. Reports First Quarter 2024 Financial Results (PR Newswire)
May-01-24 04:05PM	Penumbra, Inc. to Present at the RBC Capital Markets Global Healthcare Conference (PR Newswire)
Apr-24-24 11:43AM	Penumbra's (PEN) New Launch to Enhance Blood Clot Removal (Zacks)
Apr-23-24 09:45AM	Here's Why Penumbra (PEN) is a Strong Growth Stock (Zacks)
09:00AM	Penumbra Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots (PR Newswire)
Apr-09-24 04:05PM	Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024 (PR Newswire)
Apr-08-24 09:35AM	Here's Why You Should Retain Penumbra (PEN) Stock for Now (Zacks)
Apr-04-24 01:55AM	Insider Sell: EVP, General Counsel & Secretary Johanna Roberts Sells Shares of Penumbra Inc ... (GuruFocus.com)
Mar-05-24 09:49AM	Penumbra (PEN) Gains From Innovation, Mounting Costs Ail (Zacks)
Feb-27-24 09:45AM	Why Penumbra (PEN) is a Top Growth Stock for the Long-Term (Zacks)
Feb-26-24 11:42AM	Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase (Zacks)
Feb-23-24 11:40AM	Q4 2023 Penumbra Inc Earnings Call (Thomson Reuters StreetEvents) -9.25%
10:44AM	Penumbra, Inc. (NYSE:PEN) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:11AM	Decoding Penumbra Inc (PEN): A Strategic SWOT Insight (GuruFocus.com)
Feb-22-24 05:40PM	Penumbra (PEN) Q4 Earnings Beat Estimates (Zacks)
04:35PM	Penumbra Inc (PEN) Reports Robust Revenue Growth and Profitability in Q4 and Full Year 2023 (GuruFocus.com)
04:35PM	Penumbra: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Penumbra, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Feb-20-24 07:12AM	Here's Why You Should Retain Penumbra (PEN) Stock for Now (Zacks)
Feb-18-24 01:26PM	25 Most Valuable Medical Device Companies in the US (Insider Monkey)
Feb-15-24 10:00AM	Penumbra (PEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-01-24 04:05PM	Penumbra, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 22, 2024 (PR Newswire)
Jan-18-24 11:39AM	Penumbra (PEN) Rides on Vascular Arm Strength Amid FX Woes (Zacks)
Dec-22-23 09:37AM	Penumbra (PEN) Stock Up 16.2% YTD: Will the Rally Continue? (Zacks)
Dec-21-23 07:01AM	Is Penumbra (PEN) a Good Short Position? (Insider Monkey)
Dec-19-23 10:30AM	Here's Why You Should Invest in Penumbra (PEN) Stock Now (Zacks)
Dec-18-23 07:50PM	Penumbra, Inc. to Present at the J.P. Morgan 42nd Annual Healthcare Conference (PR Newswire)
Nov-30-23 09:55AM	Wall Street Analysts See a 26.89% Upside in Penumbra (PEN): Can the Stock Really Move This High? (Zacks)
07:37AM	Penumbra (PEN) Enrolls First Patient in Landmark STORM-PE Trial (Zacks)
Nov-28-23 09:54AM	Penumbra's (PEN) Expansion Moves, New Launches Aid Growth (Zacks)
09:00AM	First Patient in STORM-PE RCT Enrolled Evaluating Penumbra's Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash - for Treatment of Acute Pulmonary Embolism (PR Newswire)
Nov-17-23 01:03PM	Insider Sell Alert: EVP Johanna Roberts Sells Shares of Penumbra Inc (GuruFocus.com)
Nov-14-23 04:05PM	Penumbra, Inc. to Present at the Piper Sandler 35th Annual Healthcare Conference (PR Newswire) +5.99%
10:19AM	Here's Why You Should Retain Penumbra (PEN) Stock for Now (Zacks)
Nov-10-23 05:43PM	Penumbra Teams Up with Honor Everywhere to Bring US War Memorials to Aging Veterans (PR Newswire) +15.08%
Nov-03-23 08:59AM	Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase (Zacks)
08:29AM	Penumbra, Inc. (NYSE:PEN) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:18AM	Penumbra touts benefits of vacuum thrombectomy for PE in late-breaking data (MedTech Dive)
Nov-02-23 06:09PM	Penumbra Inc (PEN) Reports 26.8% Revenue Increase in Q3 2023 (GuruFocus.com)

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Roberts Johanna	EVP, Gen. Counsel & Secretary	Dec 02 '24	Sale	244.49	600	146,697	63,444	Dec 03 08:27 PM
Shiu Lambert	Chief Accounting Officer	Dec 03 '24	Option Exercise	12.36	5,250	64,890	25,278	Dec 03 08:27 PM
Shiu Lambert	Chief Accounting Officer	Nov 29 '24	Sale	242.56	1,798	436,123	20,682	Dec 03 08:27 PM
Shiu Lambert	Chief Accounting Officer	Dec 02 '24	Sale	243.01	654	158,929	20,028	Dec 03 08:27 PM
LAMBERT SHIU	Officer	Dec 02 '24	Proposed Sale	243.01	654	158,929		Dec 02 04:05 PM
LAMBERT SHIU	Officer	Nov 29 '24	Proposed Sale	242.56	1,798	436,123		Nov 29 01:28 PM
Elsesser Adam	CEO and President	Nov 20 '24	Sale	237.28	15,000	3,559,176	852,582	Nov 22 08:38 PM
Adam Elsesser	Affiliate	Nov 20 '24	Proposed Sale	237.11	30,000	7,113,300		Nov 20 05:42 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Nov 18 '24	Sale	239.74	600	143,843	64,044	Nov 19 08:04 PM
Elsesser Adam	CEO and President	Oct 21 '24	Sale	204.56	15,000	3,068,367	867,582	Oct 23 07:31 PM
Grewal Harpreet	Director	Oct 02 '24	Sale	190.83	166	31,678	8,697	Oct 03 07:33 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Oct 01 '24	Sale	190.76	600	114,456	60,488	Oct 03 07:32 PM
Kassing Don W.	Director	Oct 01 '24	Sale	193.93	170	32,968	835	Oct 03 07:32 PM
Grewal Harpreet	Director	Oct 02 '24	Proposed Sale	190.83	166	31,678		Oct 02 04:00 PM
Elsesser Adam	CEO and President	Sep 20 '24	Sale	197.71	15,000	2,965,646	882,582	Sep 24 07:29 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Sep 03 '24	Sale	206.22	600	123,733	61,088	Sep 05 07:48 PM
Grewal Harpreet	Director	Sep 04 '24	Sale	204.11	782	159,614	8,863	Sep 05 07:48 PM
Grewal Harpreet	Director	Sep 04 '24	Proposed Sale	204.11	782	159,614		Sep 04 04:13 PM
Johanna Roberts	Officer	Sep 03 '24	Proposed Sale	202.32	2,400	485,568		Sep 03 07:02 PM
Elsesser Adam	CEO and President	Aug 23 '24	Sale	203.37	28,380	5,771,597	897,582	Aug 26 07:46 PM
Elsesser Adam	CEO and President	Aug 22 '24	Sale	200.00	1,620	324,000	925,962	Aug 26 07:46 PM
Adam Elsesser	Affiliate	Aug 22 '24	Proposed Sale	195.21	60,000	11,712,600		Aug 22 04:49 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Aug 13 '24	Sale	175.98	600	105,587	61,688	Aug 15 07:41 PM
Elsesser Adam	CEO and President	Jul 17 '24	Sale	202.52	15,000	3,037,744	927,582	Jul 19 07:31 PM
Kassing Don W.	Director	Jul 01 '24	Sale	179.99	170	30,598	1,005	Jul 03 08:02 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Jul 01 '24	Sale	179.20	600	107,519	62,288	Jul 03 08:01 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Jun 03 '24	Sale	188.90	600	113,339	62,888	Jun 05 07:31 PM
Elsesser Adam	CEO and President	May 20 '24	Sale	200.98	15,000	3,014,734	942,582	May 22 07:38 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	May 13 '24	Sale	207.41	600	124,447	63,488	May 15 07:34 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Apr 01 '24	Sale	217.07	600	130,242	64,281	Apr 03 07:42 PM
Kassing Don W.	Director	Apr 01 '24	Sale	223.18	170	37,941	1,175	Apr 03 07:42 PM
Elsesser Adam	CEO and President	Mar 06 '24	Option Exercise	7.75	5,000	38,750	5,000	Mar 08 08:10 PM
Kassing Don W.	Director	Mar 01 '24	Sale	234.72	778	182,612	1,345	Mar 05 07:46 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Mar 01 '24	Sale	237.68	600	142,607	62,997	Mar 05 07:45 PM
Bose Arani	Director	Mar 04 '24	Sale	250.20	7,500	1,876,500	164,294	Mar 05 07:44 PM
Sarna Surbhi	Director	Jan 02 '24	Sale	247.68	85	21,053	2,295	Jan 04 07:36 PM
Grewal Harpreet	Director	Jan 03 '24	Sale	240.82	170	40,939	8,980	Jan 04 07:34 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Dec 27 '23	Option Exercise	22.04	2,450	53,998	63,597	Dec 29 07:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PEN

Penumbra Inc

Upgrade your FINVIZ experience